Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 25Active not recruiting 20Recruiting 17Terminated 6Withdrawn 2Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Specimen Handling 18Magnetic Resonance Spectroscopy 9Biopsy 9X-Rays 5Cyclophosphamide 5venetoclax 4fludarabine 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Dexamethasone 4Calcium Dobesilate 4carfilzomib 3Hyaluronoglucosaminidase 3sargramostim 2pomalidomide 2decitabine and cedazuridine drug combination 2daratumumab 2balstilimab 2Whole-Body Irradiation 2Stem Cell Transplantation 2Photons 2Melphalan 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytarabine 2Colony-Stimulating Factors 2Busulfan 2trastuzumab deruxtecan 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NIH × 1,2-diaminocyclohexaneplatinum II citrate × Clear all
NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡